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Abstract
Background: The rapid adoption of next-generation sequencing provides an efficient system for detecting somatic
alterations in neoplasms. The detection of such alterations requires a matched non-neoplastic sample for adequate
filtering of non-somatic events such as germline polymorphisms. Non-neoplastic tissue adjacent to the excised
neoplasm is often used for this purpose as it is simultaneously collected and generally contains the same tissue
type as the neoplasm. Following NGS analysis, we and others have frequently observed low-level somatic mutations
in these non-neoplastic tissues, which may impose additional challenges to somatic mutation detection as it complicates
germline variant filtering.
Methods: We hypothesized that the low-level somatic mutation observed in non-neoplastic tissues may be entirely or
partially caused by inadvertent contamination by neoplastic cells during the surgical pathology gross assessment
or tissue procurement process. To test this hypothesis, we applied a systematic protocol designed to collect multiple
grossly non-neoplastic tissues using different methods surrounding each single neoplasm. The procedure was applied in
two breast cancer lumpectomy specimens. In each case, all samples were first sequenced by whole-exome sequencing
to identify somatic mutations in the neoplasm and determine their presence in the adjacent non-neoplastic tissues. We
then generated ultra-deep coverage using targeted sequencing to assess the levels of contamination in non-neoplastic
tissue samples collected under different conditions.
Results: Contamination levels in non-neoplastic tissues ranged up to 3.5 and 20.9 % respectively in the two cases tested,
with consistent pattern correlated with the manner of grossing and procurement. By carefully controlling the conditions
of various steps during this process, we were able to eliminate any detectable contamination in both patients.
Conclusion: The results demonstrated that the process of tissue procurement contributes to the level of contamination
in non-neoplastic tissue, and contamination can be reduced to below detectable levels by using a carefully designed
collection method. A standard protocol dedicated for acquiring adjacent non-neoplastic tissue that minimizes neoplasm
contamination should be implemented for all somatic mutation detection studies.
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Background
Cancer is a genetic disease largely caused by somatic muta-
tions [1]. Identifying somatic mutations provides funda-
mental insights into the development, progression, and
personalized treatment of cancer. Recent advances in next-
generation sequencing (NGS) provide a very sensitive
means for detecting somatic mutations in cancer, but vari-
ant calling improves when matched non-neoplastic tissue
is sequenced in parallel to filter out non-somatic events,
such as germline polymorphisms or “normal” transcripts
[2]. For solid neoplasms, the most commonly used non-
neoplastic sources are blood, saliva, or non-neoplastic tis-
sue adjacent to the neoplasm [2–9]. Compared with blood
or saliva, the adjacent non-neoplastic tissue is conveniently
collected during the same surgical procedure, and often
consists of the same cell type as the neoplasm. However,
we and others have frequently observed the presence of
low level somatic mutations in these non-neoplastic adja-
cent tissues in prior studies, which imposes additional chal-
lenges in distinguishing somatic mutations from germline
polymorphisms (Additional file 1: Figure S1) [10].
The presence of somatic mutations in adjacent non-
neoplastic tissue may be explained by a “field effect” or
by simple contamination by neoplastic tissue. The con-
cept of the carcinogenesis field effect is not new, but has
been recently re-defined as epithelium with “normal”
morphology and genetic alterations that can result in the
development of an overt malignant neoplasm [11, 12].
There is considerable literature supporting the field effect
concept in malignancies from multiple organ systems
[13–20]. However, for breast cancer, in particular, at least
one report indicates that microscopically identifiable ma-
lignant cells, attributed to tumor cell contamination, are
often found in adjacent non-neoplastic breast tissue [21].
Such contamination of the matched non-neoplastic tissue
can limit the sensitivity of a genomic analysis by inad-
vertently excluding mutations that may be important
for neoplasm progression, prognosis, or treatment.
To determine if sample contamination during tissue
grossing and procurement is a major cause of the presence
of somatic mutations in non-neoplastic tissues, we system-
atically acquired multiple non-neoplastic tissues using dif-
ferent collection methods around the same neoplasm, and
assessed the presence of mutant alleles in non-neoplastic
tissues using next-generation sequencing. By comparing the
contamination levels of non-neoplastic tissues from differ-
ent collection methods, we demonstrated in this study that
neoplasm contamination can be reduced to below detect-
able levels by using a carefully designed collection method.
Methods
Specimens
The contamination problem was initially observed in a
subset of previously sequenced breast cancers where the
neoplasm, adjacent non-neoplastic tissue and matched
blood were all available (Additional file 1: Figure S1, S2).
These specimens were grossed for the general purposes
of variant discovery. The grossing procedure was not
specifically designed for evaluating contamination problem
so that information such as whether clean instruments
were used as well as the distance from the neoplasm the
non-neoplastic tissue was procured was not available. For
further and more detailed analysis of the contamination
problem specimens were collected from two breast lump-
ectomies following a written grossing and tissue procure-
ment protocol (Additional file 2: Supplemental materials:
Grossing and tissue procurement procedure for special col-
lections). Grossing was performed by a certified Pathologist
Assistant (PA). All patients were consented for specimen
collection under an institutional approved IRB protocol.
The final diagnosis for both specimens was invasive breast
carcinoma. The neoplastic cellularity of the two breast
lumpectomies was estimated to be 50 and 70 %, for
Patient1 and Patient2, respectively.
Collection of adjacent non-neoplastic samples
The two breast lumpectomies were sectioned from left
to right using one blade for the entire specimen (Fig. 1).
Grossly non-neoplastic tissue, sectioned before the
neoplasm, was designated “PA Clean” (PA: pathologist
assistant). Grossly non-neoplastic tissue, sectioned after
the neoplasm, was designated “PA Dirty”. Three tissue
samples were obtained from each of the two sectioned
lumpectomy specimens: a “PA Clean” section, a “PA
Dirty” section, and a section of the neoplasm. The “PA
Clean” section was placed in one Petri dish, while the
“PA Dirty” section and the neoplasm section were
placed in a second Petri dish (Fig. 1). Placing the “PA
dirty” section and the neoplasm section in the second
Petri dish was meant to mimic the way neoplasm and
non-neoplasm samples are often allowed to interact
during grossing (that is, without significant consideration
by the grosser regarding possible microscopic contamin-
ation of the non-neoplastic tissues).
Using a clean scalpel and forceps, the “PA Clean”
section in the first Petri dish was cut in half. The first
piece of the “PA Clean” section was cut in 300–500 mg
pieces using clean forceps and scalpel, placed in a cryo-
vial, and snap-frozen in LN2. This tissue was referred to
as “PA Clean” and “TP Clean” (TP: tissue procurement)
or “Clean/Clean”. The second piece of the clean non-
neoplastic tissue in the first Petri dish was cut in
300–500 mg pieces using the “dirty” forceps and scalpel
used to section the neoplasm in the second Petri dish
(see next paragraph), and snap-frozen. Once frozen, the
tissue was transferred into a cryovial using the “dirty”
forceps. This tissue was referred to as “PA Clean” and
“TP Dirty”, or “Clean/Dirty” (Fig. 1).
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Using a new set of scalpel and forceps, the neoplasm
section in the second Petri dish was cut into 300–
500 mg pieces. A neoplasm fragment was snap frozen in
a container with liquid nitrogen (LN2) and transferred to
a cryovial. Using a new set of scalpel and forceps, the
“PA Dirty” section (also located in the second Petri dish)
was cut in half. The first piece of the “PA Dirty” section
was cut in 300–500 mg pieces, placed into another cryo-
vial and snap-frozen. Once frozen, the tissue was trans-
ferred into a cryovial using the “clean” forceps. This
tissue is referred to as PA “Dirty” and TP “Clean”, or
“Dirty/Clean”. The second “PA Dirty” section was cut in
300–500 mg pieces using the “dirty” forceps and scalpel
previously used to section the neoplasm fragment (see
beginning of this paragraph) and placed directly in the
container with LN2. Once frozen, the tissue was trans-
ferred to a cryovial using the “dirty” forceps. This tissue
was referred to as “PA Dirty” and “TP Dirty”, or “Dirty/
Dirty”.
To histologically evaluate the procured tissues, they
were removed from storage and frozen sections were cut
for the pathologist’s review. For each case, QC slides
were cut, stained with H&E, and assessed by a patholo-
gist for the presence of neoplasm or absence of neo-
plasm. The full grossing procedure is in the Additional
file 2: Supplemental Methods Section.
A matched peripheral blood sample was collected
peri-operatively. DNA from the frozen breast tissues
and the matched peripheral blood were extracted fol-
lowing standard DNA extraction SOPs (Additional file 2:
Supplemental methods).
Whole-exome sequencing
Individual exome capture of each DNA sample followed
by single-indexed library generation was carried out using
a SureSelect XT All Exon V5 kit (Agilent Technologies,
Inc). Three micrograms of genomic DNA from each sam-
ple was fragmented to a size range of 150–200 bp followed
by end repair, adaptor ligation, and six cycles of PCR amp-
lification. Libraries were purified and validated for appro-
priate size (225–275 bp) on a 2100 Bioanalyzer DNA1000
chip (Agilent Technologies, Inc.). 750 ng of purified library
were then hybridized to the SureSelectXT All exon V5
Capture library for 18 h at 65 °C. The captured regions
were then bound to streptavidin magnetic beads and
washed to remove any non-specific bound products. The
eluted library underwent a second 12 cycle PCR amplifica-
tion to add sample specific barcodes for multiplexing.
Final libraries were purified, validated by a bionanalyzer
(250–350 bp), and quantitated using a KAPA qPCR
library quantitation kit (Kapa Biosystems). Individual li-
braries were pooled at equimolar 2 nM final concentration.
Fig. 1 Design of the special collection of non-neoplastic breast tissue. After orienting, the lumpectomies were bread-loafed from left to right
using one blade for the entire specimen. Non-neoplastic tissue sectioned before the neoplasm was designated “PA Clean”. Non-neoplastic tissue
sectioned after the neoplasm was designated “PA Dirty”. The forceps, scalpel, and Petri dish used to cut the neoplasm were referred to as “dirty”
tools (red). The forceps, scalpel, and Petri dish that had no contact with the neoplasm were referred to as “clean” tools (blue). During the tissue
procurement process, samples collected with “clean” tools and “dirty” tools were designated “TP Clean” and “TP Dirty”, respectively. Except for a
section of neoplasm, four samples were collected from each lumpectomy: “PA Clean” and “TP Clean” (Clean/Clean), “PA Clean” and “TP Dirty”
(Clean/Dirty), “PA Dirty” and “TP Clean” (Dirty/Clean), “PA Dirty” and “TP Dirty” (Dirty/Dirty). Grossly non-neoplastic tissue fragments that had
contact with neoplastic tissue have specs of red which are reflective of theoretical contamination
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Each pool was normalized to 10 pM, loaded, and clustered
to individual lanes of a HiSeq Flow Cell using an Illumina
cBot (TruSeq PE Cluster Kit v3), followed by 2 × 101 PE
sequencing on a HiSeq2500 sequencer according to the
manufacturer's recommended protocol (Illumina, Inc.).
Targeted amplicon sequencing
The sequencing libraries were prepared using a two-step
PCR method targeting approximately 300 bp surrounding
the somatic variants of interest. Primers targeting the
genomic regions were designed using Primer3 software
(http://bioinfo.ut.ee/primer3-0.4.0/) and forward adaptor
sequence 5’-TCGTCGGCAGCGTCAGATGTGTATAAG
AGACAG-3’ and reverse adaptor sequence 5’-GTCTC
GTGGGCTCGGAGATGTGTATAAGAGACAG-3’ were
added to the primers necessary for the second round PCR
amplification. The first round PCR utilized a gradient
annealing temperature which decreased by 1 °C per cycle
from 68 to 58 °C followed by 25 cycles with a 57 °C
annealing temperature and 72 °C extension and 94 °C
denature steps. Genomic (12.5 ng) DNA was used to amp-
lify each of the target regions. After purification with
AMPureXP beads (Beckman Coulter) and analysis on a
Bioanalyzer DNA1000 chip (Agilent Technologies, Inc.) to
ensure the desired target size, the amplicons from the
same sample were normalized and pooled to a total of
15 ng using quantitation data from the Bioanalyzer.
The amplicon pool from the first round PCR was amp-
lified with eight cycles of PCR using a Nextera Index
Kit (Illumina, Inc.), which uses primers that target the
overhang adaptor sequence incorporated during the
first round of PCR to add a unique indexed tag to each
sample which allows pooling of libraries and multiplex se-
quencing. Indexed libraries were purified with AMPureXP
beads, run on a Bioanalyzer DNA1000 chip to verify de-
sired size distribution, quantitated using a KAPA qPCR
library quantitation kit (Kapa Biosystems) and pooled in
an equimolar fashion to a final concentration of 4 nM.
2 × 150 cycle sequencing was performed on a MiSeq
(Illumina, Inc.), according to the manufacturer’s protocol.
Somatic mutation detection from neoplasm and the
matched blood samples
High quality paired-end reads passing the Illumina RTA
filter were aligned to the NCBI human reference genome
(hg19) using Burrows-Wheeler Aligner [22]. PCR dupli-
cated reads were marked and removed by using Picard
(http://broadinstitute.github.io/picard/). Putative SNVs
and Indels were identified by running the variation detec-
tion module of Bambino [23]. After initial variant calling,
the predicted mutations were further filtered to remove po-
tential false calls: (1) the alternative allele is present in the
matched blood sample and the Fisher’s exact test P value
not less than 0.05; (2) the mutant alleles are only present in
one of the two strands and the Fisher’s exact test p < 0.05;
(3) the putative mutation occurs at a site with systematically
dropped base quality scores, defined as more than 70 % of
the mutant reads with Phred quality score reduced by at
least 10 at the mutant base compared with the 5’ or 3’ side
neighboring bases. All identified mutations were manually
reviewed using Bambino viewer (Edmonson, Zhang et al.
[23]). The functional effects were predicted by ANNOVAR
[24] using RefSeq sequence database downloaded from
NCBI on March 22, 2015.
Assessing contamination in non-neoplastic samples
For each somatic mutation identified from the neoplasm
whole-exome sequencing (WES) data, the mutation site
was re-sequenced in all matched blood and non-neoplastic
adjacent tissue, by either WES or TAS. The NGS reads at
the mutation site were extracted from the BAM file and
classified by mutation status into three groups: mutant,
non-mutant (wild-type or a different allele), and unknown
(e.g. low base quality). The mutation statuses of paired
reads were consolidated and any read pairs where the for-
ward and reverse reads had conflicting mutant status were
excluded from the analysis. The coverage and VAF were
calculated based on mutant and non-mutant read pairs.
In WES, the relative contamination levels between
samples were compared by using fractions of SNVs
present in non-neoplastic data with at least one mutant
read. In TAS, the contamination level in terms of the
percentage of neoplasm content in each non-neoplastic
sample was estimated by: (VAF_in_non-neoplastic_tissue -
VAF_in_blood)/VAF_in_neoplasm based on individual
SNVs.
Results
In the process of procuring tissue for NGS of clinical
samples, we have frequently detected the presence of
low level, presumptive somatic alterations in non-
neoplastic tissue adjacent to the neoplasm being ana-
lyzed (Additional file 1: Figure S1). In one example, a
somatic BRCA2 nonsense mutation in a breast cancer
case was detected in both neoplasm and the matched
adjacent non-neoplastic tissues at 23 and 2 % variant
allele fractions (VAFs), respectively (Additional file 1:
Figure S2). In these preliminary observations, one pos-
sible source of neoplasm contamination was the sample
grossing and procurement process, during which the
non-neoplastic tissue may have come into contact
(directly or indirectly through operational tools) with
neoplastic tissue. Although “molecular precautions”
are routinely used during the histological sectioning of
formalin-fixed paraffin-embedded (FFPE) samples [25],
there are no corresponding standards for obtaining fresh,
adjacent non-neoplastic tissue during the initial pro-
cessing of tumor specimens in gross sectioning.
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Due to the high sensitivity of NGS, standard grossing
procedures may lead to frequent detection of contamin-
ation in the adjacent non-neoplastic tissues, resulting in
decreased somatic mutation detection sensitivity. There-
fore, we evaluated two breast lumpectomies using a sys-
tematic protocol for non-neoplastic sample collection
designed to determine if the level of apparent contamin-
ation can be affected by the specimen grossing and tis-
sue procurement process (Fig. 1). The overall workflow
of adjacent sample collection consists of two processes:
Pathologist Assistant (PA) directed process and the
Tissue Procurement (TP) process. For each of these two
processes, we defined two conditions, referred to as
“Clean” and “Dirty”, to denote different scenarios that pre-
sumably lead to varying levels of contamination. These
collection scenarios yield four types of adjacent non-
neoplastic samples (described in detail in the Methods
section): “Clean/Clean”, “Clean/Dirty”, “Dirty/Clean”, and
“Dirty/Dirty”. The level of contamination in adjacent non-
neoplastic tissues was assessed by comparing the adjacent
tissues with a blood sample from the same individual,
using whole-exome sequencing (WES) followed by tar-
geted amplicon sequencing (TAS). An analytic flow chart
identifies all steps in this process (Fig. 2), which consists
of three sets of sequence determination: 1) identification
of de novo mutations in the neoplastic tissue which then
served as genetic markers of neoplasm contamination; 2)
confirmation of the presence of these somatic mutations
in the non-neoplastic samples; 3) precise measurement of
contamination levels by comparing each non-neoplastic
sample to blood. The first two goals were achieved by
using WES. For the third goal, we used TAS to generate
the needed ultra-deep coverage.
Identification of somatic mutations and initial assessment
of tumor contamination using whole-exome sequencing
Whole exome sequencing was performed on six sample
types (neoplastic, blood, and four types of non-neoplastic
tissues for evaluation purpose) for each of the two pa-
tients. We generated an average of 193 million reads per
sample, with mapping rate ranged from 94 to 99 %. The
average coverage within the targeted region ranged from
85.6X to 279.3X in all samples, with a median of 206.3X.
Most samples (10 of 12) had above 80 % of the targeted
regions covered with at least 30X coverage (Additional
file 3: Table S1).
Putative somatic mutations were identified by comparing
neoplasm sample with the matched blood sample. In the
current study, only single nucleotide variants (SNVs) were
used in the estimation of neoplasm contamination. Small
insertion/deletions (Indels) were excluded to avoid poten-
tial bias due to the difficulty in mapping reads harboring
Fig. 2 Overall flow chart of the two-stage analysis strategy. a, de-novo mutation calling and initial assessment of neoplasm contamination by
using WES; b, targeted validation and ultra-deep sequencing to assess neoplasm contamination level in each adjacent non-neoplastic tissue.
WES: whole exome sequencing; TAS: targeted amplicon sequencing; SNV: single nucleotide variant; VAF: variant allele fraction
Wei et al. BMC Medical Genomics  (2016) 9:64 Page 5 of 10
Indels [26]. For the current two breast carcinoma samples,
we identified a total of 52 putative somatic SNVs (Fig. 2,
Additional file 4: Table S2).
These SNVs were then used as markers to assess neo-
plasm contamination in the WES data of the four types
of non-neoplastic tissue samples. A minimum 20X
coverage at the mutation site in all related samples was
required, retaining 45 out of the 52 SNVs, including 31
in Patient1, 14 in Patient2 (Additional file 4: Table S2).
The first indication of contamination was the evidence
of somatic SNVs present in non-neoplastic tissue: in
Patient1, Clean/Clean: 3 % (1/31), Clean/Dirty: 19 %
(6/31), Dirty/Clean: 52 % (16/31), and Dirty/Dirty:
32 % (10/31), or 33 occurrences in total, had variant
allele fraction (VAF) greater than zero. Of these, eight
occurrences had VAFs between 1 and 5 % and the rest
were less than 1 %. Noticeably, in Patient1, one SNV
was present under the condition “Clean/Clean”. Upon
further manual review of the raw BAM file, this SNV
in gene CELF6 (Additional file 4: Table S2) had two
mutant reads with the same read id, suggesting these
two reads were from the same DNA insert (data not
shown), possibly reflected artifacts during library prep-
aration. In Patient2, none of the SNVs were present in
the first three conditions (Clean/Clean, Clean/Dirty,
and Dirty/Clean), but most SNVs (93 %, or 13/14, in-
cluding four SNVs between 1 and 5 % and nine over
5 %) were present in the Dirty/Dirty condition (Fig. 3).
No SNVs were present in the blood sample in either
case. Due to the limited coverage (Additional file 3:
Table S1), these results by WES should only be considered
as a first indication and might not accurately reflect con-
tamination levels.
Accurate measurement of tumor contamination in
non-neoplastic tissues using ultra-deep targeted
amplicon sequencing
To obtain more precise measurements of neoplasm con-
tamination level, ultra-deep coverage at the identified
mutation sites was obtained using targeted amplicon se-
quencing (TAS). TAS was first performed to confirm the
NGS SNVs detected in the neoplasm and matched blood
samples. Ten out of 52 SNVs had PCR failure and were
excluded from further analyses. For the remaining pre-
dicted SNVs, 41 of 42 were validated as somatic muta-
tions, and one was determined to be a false positive.
This false call did not affect the previous WES results
(Fig. 3) because this variant was among the seven ex-
cluded variants that did not meet the minimum 20X
coverage requirement as shown in the overall flow chart
(Fig. 2). The 41 validated somatic SNVs were then evalu-
ated by TAS of all four types of adjacent non-neoplastic
samples. A minimum coverage of 5000X in all TAS
samples was required for all SNVs; four SNVs did not
meet this requirement and were excluded from further
analyses. For the 37 remaining SNVs (25 in Patient1, 12
in Patient2), the median coverage of each SNV across
Fig. 3 Presence of somatic SNVs in adjacent non-neoplastic tissues as the first indication of contamination. Distribution of somatic SNVs’ allele
fractions (VAF) in WES data of the blood and four types of adjacent non-neoplastic tissues, classified by four categories: zero (no mutant reads
detected), less than one percent, one to five percent, and greater than five percent. Y axis values represent the numbers of SNVs in each category
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all TAS samples ranged from 17,585X to 158,918X
(Additional file 1: Figure S3).
The allele fractions of most SNVs ranged from 10 to
30 %, and were overall consistent between the two plat-
forms (between WES and TAS: r2 = 0.8663 and 0.7443 in
Patient1 and Patient2, respectively) (Additional file 1:
Figure S4). The neoplasm contamination levels were es-
timated based on individual SNVs in all evaluated non-
neoplastic samples. In Patient1, the medians of neoplasm
contamination levels estimated by the 25 SNVs were 0.0,
0.2, 2.2, and 3.5 % for the four types of non-neoplastic
samples (Clean/Clean, Clean/Dirty, Dirty/Clean, and Dirty/
Dirty), respectively. In Patient2, based on the 12 qualified
SNVs, the median contamination levels were 0.0, 0.3, 0.0,
and 20.9 % (Fig. 4, Additional file 5: Table S3).
Discussion
Tissue contamination is a well-known pitfall in path-
ology laboratories and tissue processing [27], and is a
particular challenge for NGS-based somatic alteration
analyses because of the high sensitivity of this technique.
The contamination of non-neoplastic tissue with low
levels of mutant nucleic acids can cause somatic muta-
tions to be misclassified as germline events and subse-
quently be excluded from further analysis. Attempting to
bioinformatically ‘rescue’ these missing somatic muta-
tions is an additional challenge and may result in a high
false positive rate. These problems are best solved by min-
imizing neoplasm contamination during sample gross-
ing and procurement. However, until now, the relation
between methods of non-neoplastic sample collection and
neoplasm contamination has not been formally addressed.
In this investigation, we tried to mimic the procedures
that may occur during multiple steps of non-neoplastic
tissue collection. Our results provide clear evidence that
neoplasm contamination in adjacent non-neoplastic
samples can be reduced by optimizing the collection
protocol at every step. In both tested lumpectomies, the
“Clean/Clean” protocol was shown to have the lowest
level of contamination, while the "Dirty/Dirty" protocol
generated the highest level of contamination (Fig. 4).
The lumpectomy from Patient1 had an incremental pro-
gression of increasing estimated neoplasm contamin-
ation from Clean/Clean, to Clean/Dirty, to Dirty/Clean,
to Dirty/Dirty. This suggests that both “Pathologist
Assistant” and “Tissue Procurement” stages could con-
tribute to contamination. However, the specimen from
Patient2 did not have such an incremental progression.
Instead, there was a relatively small amount of contami-
nation in the Clean/Dirty condition, no contamination
in the Dirty/Clean condition, and very high relative con-
tamination in the Dirty/Dirty condition. This suggests
that there was no carryover of neoplasm when the speci-
men was initially sectioned. One possible explanation is
Fig. 4 The estimated contamination levels in adjacent non-neoplastic tissues by targeted amplicon sequencing. Each red dot represents a previously
identified somatic SNV. The contamination level was estimated by: (VAF_in_non-neoplastic_tissue - VAF_in_blood)/VAF_in_neoplasm. The median
contamination levels for each non-neoplastic sample are plotted as a horizontal bar with the percentage displayed in numeric value
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that during the initial sectioning of the specimen, neo-
plastic cells were carried over mostly in the sections im-
mediately after the neoplasm. Sampling from the less-
contaminated distal portions of the specimen may ex-
plain the lack of contamination. However, since we did
not keep track of the distance between the neoplasm
and the tissue subsequently tested for contamination, we
cannot evaluate further.
It is worth re-iterating that in the “PA dirty” condition,
non-neoplastic tissue and a neoplasm section were
placed in the same Petri dish to mimic the way neo-
plasm and non-neoplasm samples are often allowed to
interact during grossing. As such, contamination that
occurred during the initial sectioning of the specimen
and contamination that occurred during the interaction
of neoplasm and non-neoplastic tissue in the Petri dish
cannot be distinguished.
Despite the fact that the neoplastic cellularity was esti-
mated to be 50 and 70 % for Patient1 and Patient2, re-
spectively, the VAF of the detected variants by WES and
TAS tended to be significantly lower (Additional file 1:
Figure S4). There are various possible explanations for
this such as heterozygous status, over-representation of
non-neoplastic cells, copy number changes, and hetero-
geneity within the neoplasm.
Another possible explanation of the presence of vari-
ants in non-neoplastic tissue is field effect. Previously,
oncogenic copy number gains in common breast cancer
driver genes had been found in microscopically normal
breast cells outside the tumor [28]. Due to the scope of
the current study, we did not assess the possibility of a
field effect in a detailed fashion, which would require
sampling of non-neoplastic tissues at various distance
intervals from the neoplasm. Also, we did not consider
the potential effect of circulating tumor cells or tumor
DNA. Since the variants were not detectable under
Clean/Clean condition by deep sequencing, field effect
or circulating tumor cells or DNA is unlikely to be the
major cause in the current study.
Most variants caused by contamination in non-
neoplastic data appeared to be low frequency event
(<10 %) in the current WES. Previous study on cross-
patient contamination showed that as little as 2 % con-
taminations could cause significant increase of mutation
burden due to false positives [29, 30]. For within-patient
contaminations in control sample, to the best of our
knowledge, there has been no systematic evaluation pub-
lished on the effects on somatic mutation calling. Since
algorithms have different levels of tolerance for muta-
tions present in control, the ones with higher tolerance
may lose fewer variants, but at the cost of increased false
positive due to germline events. A safer approach might
be excluding control samples with known contamination
issues [31].
For future somatic analyses involving germline gen-
etic material, using peripheral blood or other difficult-
to-contaminate tissues as sources is a reasonable strategy.
However, when grossed material is the only source of
non-neoplastic sample, a specialized grossing protocol will
be beneficial. First, the individual grossing the specimen
should always be aware of the gross features of neoplasms.
Second, clean non-neoplastic tissue should be collected
from an area sectioned before the neoplasm is sectioned.
Third, the non-neoplastic tissue and neoplasm/neo-
plasm-contaminated-tissue should be processed in sep-
arate work areas. Finally, the instruments used to cut
the non-neoplastic tissue should be clean instruments
that have not previously come in contact with the
neoplasm.
Conclusions
We have demonstrated that clean grossing and procure-
ment techniques can minimize the chance of neoplasm
contamination in adjacent non-neoplastic tissue, which
may improve the detection of somatic mutation. Al-
though this is a pilot study that included only two lump-
ectomy specimens and the analysis consisted of DNA
sequencing alone, our results provide clear evidence that
the methods used in sample grossing and procurement
can play a non-trivial role in obtaining high quality non-
neoplastic tissue samples. It is important that protocols
for tissue grossing and procurement account for con-
tamination reduction measures, thereby facilitating the
acquisition of high quality, non-contaminated adjacent
non-neoplastic tissues which can be used to maximize
the accuracy of molecular testing.
Availability of supporting data
The following additional data are available with the on-
line version of this paper. “Table_S1_coverage_summary_
WES.xlsx” is a table containing the mapping statistics
and coverage summary of each of the 12 samples in
whole-exome sequencing. “Table_S2_Somatic_SNVs_
in_WES.xlsx” is a table containing all variants identified
by whole-exome sequencing with coverage and VAF
information; “Table_S3_VAF_by_TAS.xlsx” is a table
containing the coverage, variant allele fraction and esti-
mated contamination level for each variant by targeted
amplicon sequencing; “Figures_v2.52_suppl.pptx” is a
PowerPoint file contains four supplementary figures;
“EVNC2.52_suppl.docx” is a word document containing
the supplementary methods, description of the supple-
mentary tables, and the legend of supplementary
figures. The sequencing data from the tumors, adja-
cent non-neoplastic tissues and normal blood samples
has been submitted to the NCBI Database of Geno-
types and Phenotypes (dbGaP) under study accession
[accession no. placeholder].
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Additional files
Additional file 1: Supplementary figures S1-4. Figure S1. An example of
previous observation of neoplasm contamination in adjacent non-neoplastic
tissues. Figure S2. An example of one somatic mutation (BRCA2S3041*)
present in the matched normal data from adjacent non-neoplastic tissue.
Figure S3. Coverage by targeted capture sequencing (TAS). Figure S4.
Concordance of variant allele fraction (VAF) between whole-exome
sequencing (WES) and targeted capture sequencing (TAS). (PPTX 925 kb)
Additional file 2: Supplementary methods, description of tables, figure
legends and references. (DOCX 33 kb)
Additional file 3: Table S1. Coverage summary of whole-exome se-
quencing (WES). (XLSX 12 kb)
Additional file 4: Table S2. Detailed information of all somatic
mutations identified by WES, including coverage, variant allele fraction
(VAF) and the predicted amino acid changes. (XLSX 19 kb)
Additional file 5: Table S3. Detailed information of all somatic
mutations in targeted amplicon sequencing (TAS), including coverage,
VAF and estimated contamination level. (XLSX 20 kb)
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